Promising drug for rare blood disorder trial halted early

NCT ID NCT05073458

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tested the drug parsaclisib in people with primary warm autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. The trial aimed to see if parsaclisib could improve hemoglobin levels and reduce fatigue compared to a placebo. However, the study was terminated early after enrolling only 13 participants, so the results are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: parsaclisib
What this could lead to: If successful, parsaclisib could offer a new treatment option for people with warm autoimmune hemolytic anemia who have not responded to other therapies.
What could go wrong: The trial was terminated early with only 13 participants, so results are limited. It is unclear if parsaclisib is effective or safe for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia, warm type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA)

Contacts and locations

Locations

Investigative Site AT001

Vienna, 01090, Austria
Investigative Site AT002

Salzburg CET, A-5020, Austria
Investigative Site BE001

La Louvière, 07100, Belgium
Investigative Site BE002

Liège, 04000, Belgium
Investigative Site CA001

Edmonton, Alberta, T6G 2P4, Canada
Investigative Site DE001

Essen, 45147, Germany
Investigative Site DE002

Ulm, 89081, Germany
Investigative Site ES001

Barcelona, 08036, Spain
Investigative Site ES002

Valencia, 46026, Spain
Investigative Site ES003

Madrid, 28006, Spain
Investigative Site ES004

Tarragona, 43005, Spain
Investigative Site ES005

Murcia, 30008, Spain
Investigative Site ES006

Badalona, 08916, Spain
Investigative Site FR001

Paris, 75015, France
Investigative Site FR002

Lille, 59037, France
Investigative Site FR003

Marseille, 13285, France
Investigative Site GB002

Glasgow, G4 0SF, United Kingdom
Investigative Site GB003

Norwich, NR4 7UY, United Kingdom
Investigative Site GB004

Plymouth, PL6 8DH, United Kingdom
Investigative Site GB005

Reading, RG1 5AN, United Kingdom
Investigative Site GB006

London, W12 0HS, United Kingdom
Investigative Site IL001

Nahariya, 2210001, Israel
Investigative Site IL002

Haifa, 31096, Israel
Investigative Site IT001

Novara, 28100, Italy
Investigative Site IT002

Milan, 20122, Italy
Investigative Site IT003

Florence, 50134, Italy
Investigative Site IT004

Pavia, 27100, Italy
Investigative Site IT005

Trieste, 34125, Italy
Investigative Site IT006

Rome, 00168, Italy
Investigative Site JP001

Suita-shi, 565-0871, Japan
Investigative Site JP002

Okayama, 701-0192, Japan
Investigative Site JP003

Tokyo, 141-8625, Japan
Investigative Site JP004

Isehara, 259-1193, Japan
Investigative Site JP005

Saitama, 350-0495, Japan
Investigative Site JP006

Nagoya, 467-8602, Japan
Investigative Site JP007

Sendai, 980-8574, Japan
Investigative Site JP008

Fukuoka, 807-8556, Japan
Investigative Site JP009

Okayama, 700-8557, Japan
Investigative Site JP010

Osakasayama-shi, 589-8511, Japan
Investigative Site NL001

Rotterdam, 3015CA, Netherlands
Investigative Site PL001

Legnica, 59220, Poland
Investigative Site PL002

Wroclaw, 53-439, Poland
Investigative Site PL003

Nowy Sącz, 33-300, Poland
Investigative Site PL004

Wałbrzych, 58-309, Poland
Investigative Site PL005

Opole, 45-372, Poland
Investigative Site PL006

Lodz, 93-510, Poland
Investigative Site US001

Knoxville, Tennessee, 37920, United States
Investigative Site US002

The Bronx, New York, 10467, United States
Investigative Site US003

Greenville, North Carolina, 27858, United States
Investigative Site US004

Whittier, California, 90603, United States
Investigative Site US005

Los Angeles, California, 90089, United States
Investigative Site US006

Miami, Florida, 33165, United States
Investigative Site US007

The Bronx, New York, 10461, United States
Investigative Site US009

Canton, Ohio, 44718, United States
Investigative Site US010

Easton, Pennsylvania, 18045, United States
Investigative Site US012

Indianapolis, Indiana, 46260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.